TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Show more

Location: 1 Great Valley Parkway, Malvern, PA, 19355, United States | Website: https://www.telabio.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

65.37M

52 Wk Range

$0.86 - $3.26

Previous Close

$1.65

Open

$1.66

Volume

64,224

Day Range

$1.56 - $1.71

Enterprise Value

72.49M

Cash

34.98M

Avg Qtr Burn

-8.536M

Insider Ownership

8.98%

Institutional Own.

73.05%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date